Shigefumi Fukui

Dr. Shigefumi Fukui

Fujita Health University, Toyoake, Aichi, Japan
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in International Journal of Cardiology
Verified
Journal Article
Closed access
RARyotaro Asano
Ryotaro Asano
TOTakeshi Ogo
Takeshi Ogo
KOKeiko Ohta-Ogo
Keiko Ohta-Ogo
SFShigefumi Fukui
Shigefumi Fukui
ATAkihiro Tsuji
Akihiro Tsuji
SYSatoshi Yasuda
Satoshi Yasuda

25 April 2019 in Circulation Journal
Verified
Journal Article
Open access
PDF file
RARyotaro Asano
Ryotaro Asano
SFShigefumi Fukui
Shigefumi Fukui
TNTatsuya Nishii
Tatsuya Nishii
NKNao Konagai
Nao Konagai
THTakuya Hasegawa
Takuya Hasegawa
SYSatoshi Yasuda
Satoshi Yasuda
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

1 January 2022 in Pulmonary Circulation
Verified
Journal Article
Open access
PDF file
DADaisetsu Aoyama
Daisetsu Aoyama
SFShigefumi Fukui
Shigefumi Fukui
HHHaruhiko Hirata
Haruhiko Hirata
KOKeiko Ohta‐Ogo
Keiko Ohta‐Ogo
HMHideo Matama
Hideo Matama
SYSatoshi Yasuda
Satoshi Yasuda
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rapidly progressive subtype of pulmonary hypertension (PH) associated with impaired right ventricular adaptation and very poor prognosis in cancer, and its rapid progression makes antemortem diagnosis and treatment extremely difficult. We describe the case of a 35‐year‐old woman who developed severe PH with subsequent circulatory collapse. The patient was clinically diagnosed with PTTM induced by lung adenocarcinoma harboring the c‐ros oncogene 1 (ROS1) rearrangement within 1–2 weeks, while hemodynamics were stabilized by rescue venoarterial extracorporeal membrane oxygenation support. Crizotinib, an oral tyrosine kinase inhibitor targeting anaplastic lymphoma kinase, MET, and ROS1 kinase domains dramatically resolved PH, resulting in more than 3 years of survival. Targeted gene‐tailored therapy with mechanical support can improve survival in PTTM.

28 April 2024 in Pulmonary Circulation
Verified
Journal Article
Open access
TSTsukasa Sato
Tsukasa Sato
SFShigefumi Fukui
Shigefumi Fukui
TNTakao Nakano
Takao Nakano
KHKaoru Hasegawa
Kaoru Hasegawa
HKHisashi Kikuta
Hisashi Kikuta
TKTatsuya Komaru
Tatsuya Komaru
Chronic thromboembolic pulmonary hypertension (CTEPH) is a chronic disease that can rapidly deteriorate into circulatory collapse when complicated by comorbidities. We herein describe a case involving a 43‐year‐old woman with class III obesity (body mass index of 63 kg/m2) and severe CTEPH associated with total occlusion of the left main pulmonary artery who subsequently developed circulatory collapse along with multiple comorbidities, including acute kidney injury, pulmonary tuberculosis, and catastrophic antiphospholipid syndrome. The patient was successfully treated with two sessions of rescue balloon pulmonary angioplasty with veno‐arterial extracorporeal membrane oxygenation (V‐A ECMO) support under local anesthesia without sedation, at cannulation and during the V‐A ECMO run, to avoid invasive mechanical ventilation. This case suggests the potential usefulness of rescue balloon pulmonary angioplasty under awake V‐A ECMO support for rapidly deteriorating, inoperable CTEPH in a patient with class III obesity complicated with multiple comorbidities.

30 November 2018 in International Heart Journal
Verified
Journal Article
Closed access
NKNao Konagai
Nao Konagai
SFShigefumi Fukui
Shigefumi Fukui
MKMasataka Kitano
Masataka Kitano
YAYasuhide Asaumi
Yasuhide Asaumi
MNMichio Nakanishi
Michio Nakanishi
SYSatoshi Yasuda
Satoshi Yasuda
In patients with an atrial septal defect (ASD) and left ventricular (LV) dysfunction associated with coronary artery disease (CAD), to avoid the development of acute left heart failure (HF) and an increase in myocardial oxygen consumption following ASD closure, it is conceivable that coronary artery revascularization should be performed prior to ASD closure. We report the case of a 67-year-old man with a large secundum ASD and LV ejection fraction of 15.6% resulting from severe ischemic cardiomyopathy and triple-vessel CAD, both of which contributed to biventricular HF characterized by high left-to-right shunt (Qp:Qs of 7.1:1) and low systemic cardiac output. After evaluating his hemodynamics and biventricular function with cardiac catheterization and cardiovascular magnetic resonance imaging, we successfully conducted an inverse, stepwise strategy of transcatheter ASD closure using anti-congestive therapies, intraaortic balloon pumping, and subsequent balloon occlusion testing, followed by on-pump beating-heart coronary artery bypass grafting.

6 November 2022 in Life
Verified
Journal Article
Open access
PDF file
SFShigefumi Fukui
Shigefumi Fukui
YSYuko Shirota
Yuko Shirota
TNTakao Nakano
Takao Nakano
TSTsukasa Sato
Tsukasa Sato
KHKaoru Hasegawa
Kaoru Hasegawa
TKTatsuya Komaru
Tatsuya Komaru
Balloon pulmonary angioplasty (BPA) has been reported to be effective and safe to an acceptable level in patients with distal-type, inoperable chronic thromboembolic pulmonary hypertension (CTEPH), resulting in improved long-term survival. However, evidenced treatment options and strategy including medical therapy of antithrombotic therapy, glucocorticoids, immunosuppressants, and pulmonary hypertension (PH)-specific therapies are scarce in patients with significant PH and right heart failure associated with Takayasu arteritis and peripheral pulmonary artery stenosis, both of which mimic CTEPH. Moreover, there has been still concern on safety and lack of established methodology in performing BPA for these conditions. In this report, we would like to review recent publications including several case reports and discuss the efficacy, safety, and suitable methods of BPA in this population.